Literature DB >> 23873135

A further TWEAK to multiple sclerosis pathophysiology.

Arash Nazeri1, Pouria Heydarpour, Shokufeh Sadaghiani, Mohammad Ali Sahraian, Linda C Burkly, Amit Bar-Or.   

Abstract

Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) is a member of the TNF super family that controls many cellular activities including proliferation, migration, differentiation, apoptosis, and inflammation by binding to fibroblast growth factor-inducible 14 (Fn14), a highly inducible cell surface receptor. Recent studies have indicated that TWEAK-Fn14 axis signaling may contribute to chronic autoimmune diseases. TWEAK expression via microglia in cortical lesions, presence of TWEAK(+) macrophages in inflamed leptomeninges, and absence of TWEAK/Fn14 expression in healthy brain implicates importance of this pathway in pathogenesis of multiple sclerosis lesions. TWEAK-Fn14 axis blockade has also shown promise in various multiple sclerosis animal models. Stimulation of the TWEAK/Fn14 pathway can result in activation of both canonical and noncanonical NF-κB signaling and could also stimulate mitogen-activated protein kinase (MAPK) signaling pathways. Here, we have reviewed evidence of the possible role of TWEAK-Fn14 axis in pathophysiology of multiple sclerosis and experimental autoimmune encephalomyelitis (EAE) via neuroinflammation, tissue remodeling, blood-brain barrier (BBB) disruption, neurodegeneration, and astrogliosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23873135     DOI: 10.1007/s12035-013-8490-y

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  79 in total

1.  TWEAK induces liver progenitor cell proliferation.

Authors:  Aniela Jakubowski; Christine Ambrose; Michael Parr; John M Lincecum; Monica Z Wang; Timothy S Zheng; Beth Browning; Jennifer S Michaelson; Manfred Baetscher; Manfred Baestcher; Bruce Wang; D Montgomery Bissell; Linda C Burkly
Journal:  J Clin Invest       Date:  2005-08-18       Impact factor: 14.808

Review 2.  Metalloproteinases: mediators of pathology and regeneration in the CNS.

Authors:  V Wee Yong
Journal:  Nat Rev Neurosci       Date:  2005-12       Impact factor: 34.870

Review 3.  TWEAK and TRAF6 regulate skeletal muscle atrophy.

Authors:  Ashok Kumar; Shephali Bhatnagar; Pradyut K Paul
Journal:  Curr Opin Clin Nutr Metab Care       Date:  2012-05       Impact factor: 4.294

Review 4.  TWEAK and Fn14: new molecular targets for cancer therapy?

Authors:  Jeffrey A Winkles; Nhan L Tran; Michael E Berens
Journal:  Cancer Lett       Date:  2006-04-08       Impact factor: 8.679

5.  TWEAK/Fn14 promotes apoptosis of human endometrial cancer cells via caspase pathway.

Authors:  Dengfeng Wang; Jenny Nga Ting Fung; Ya Tuo; Lina Hu; Chen Chen
Journal:  Cancer Lett       Date:  2010-02-26       Impact factor: 8.679

6.  Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study.

Authors:  M A Lee; J Palace; G Stabler; J Ford; A Gearing; K Miller
Journal:  Brain       Date:  1999-02       Impact factor: 13.501

7.  Pro-inflammatory effect of TWEAK/Fn14 interaction on human umbilical vein endothelial cells.

Authors:  Norihiro Harada; Masafumi Nakayama; Hiroyasu Nakano; Yoshinosuke Fukuchi; Hideo Yagita; Ko Okumura
Journal:  Biochem Biophys Res Commun       Date:  2002-12-06       Impact factor: 3.575

Review 8.  TWEAK and the central nervous system.

Authors:  Manuel Yepes
Journal:  Mol Neurobiol       Date:  2007-06       Impact factor: 5.590

9.  Elevated matrix metalloproteinase-9 and degradation of perineuronal nets in cerebrocortical multiple sclerosis plaques.

Authors:  Elizabeth Gray; Taya Louise Thomas; Samar Betmouni; Neil Scolding; Seth Love
Journal:  J Neuropathol Exp Neurol       Date:  2008-09       Impact factor: 3.685

10.  TWEAK binding to the Fn14 cysteine-rich domain depends on charged residues located in both the A1 and D2 modules.

Authors:  Sharron A N Brown; Heather N Hanscom; Hong Vu; Shelesa A Brew; Jeffrey A Winkles
Journal:  Biochem J       Date:  2006-07-15       Impact factor: 3.857

View more
  5 in total

1.  A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo.

Authors:  Johannes Trebing; Isabell Lang; Martin Chopra; Steffen Salzmann; Mahan Moshir; Karen Silence; Simone S Riedel; Daniela Siegmund; Andreas Beilhack; Christoph Otto; Harald Wajant
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

Review 2.  Drug Trafficking into Macrophages via the Endocytotic Receptor CD163.

Authors:  Jonas Heilskov Graversen; Søren Kragh Moestrup
Journal:  Membranes (Basel)       Date:  2015-06-23

3.  TWEAK/Fn14 Axis-Targeted Therapeutics: Moving Basic Science Discoveries to the Clinic.

Authors:  Emily Cheng; Cheryl L Armstrong; Rebeca Galisteo; Jeffrey A Winkles
Journal:  Front Immunol       Date:  2013-12-23       Impact factor: 7.561

Review 4.  Regulation of Neuroinflammation: What Role for the Tumor Necrosis Factor-Like Weak Inducer of Apoptosis/Fn14 Pathway?

Authors:  Audrey Boulamery; Sophie Desplat-Jégo
Journal:  Front Immunol       Date:  2017-11-16       Impact factor: 7.561

5.  Microglial Nox2 Plays a Key Role in the Pathogenesis of Experimental Autoimmune Encephalomyelitis.

Authors:  Chih-Fen Hu; San-Pin Wu; Gu-Jiun Lin; Chi-Chang Shieh; Chih-Sin Hsu; Jing-Wun Chen; Shih-Heng Chen; Jau-Shyong Hong; Shyi-Jou Chen
Journal:  Front Immunol       Date:  2021-04-02       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.